[Skip to Content]
[Skip to Content Landing]

Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure

Educational Objective
To understand the potential role of clonal hematopoiesis of indeterminate potential in the pathogenesis of ischemic heart failure.
1 Credit CME
Key Points

Question  What is the clinical significance of clonal hematopoiesis of indeterminate potential (CHIP) for chronic heart failure (CHF) owing to ischemic origin?

Findings  In this cohort study, CHIP had a high prevalence in 200 investigated patients with CHF. While no clinical baseline characteristics associated with CHF were different between CHIP carriers and non-CHIP carriers, except for the mean age, harboring mutations in the most prevalent driver genes associated with CHIP, namely DNMT3A and TET2, was associated with a significant and profound increase in death and rehospitalization for heart failure.

Meaning  Clonal hematopoiesis of indeterminate potential is presented as a newly identified risk factor for impaired long-term survival and increased disease progression in patients with CHF that may be well targetable as a valuable approach to precision medicine in patients with CHF carrying specific mutations encoding for clonal hematopoiesis.

Abstract

Importance  Somatic mutations causing clonal expansion of hematopoietic cells (clonal hematopoiesis of indeterminate potential [CHIP]) are increased with age and associated with atherosclerosis and inflammation. Age and inflammation are the major risk factors for heart failure, yet the association of CHIP with heart failure in humans is unknown.

Objective  To assess the potential prognostic significance of CHIP in patients with chronic heart failure (CHF) owing to ischemic origin.

Design, Setting, and Participants  We analyzed bone marrow–derived mononuclear cells from 200 patients with CHF by deep targeted amplicon sequencing to detect the presence of CHIP and associated such with long-term prognosis in patients with CHF at University Hospital Frankfurt, Frankfurt, Germany. Data were analyzed between October 2017 and April 2018.

Results  Median age of the patients was 65 years. Forty-seven mutations with a variant allele fraction (VAF) of at least 0.02 were found in 38 of 200 patients with CHF (18.5%). The somatic mutations most commonly occurred in the genes DNMT3A (14 patients), TET2 (9 patients), KDM6A (4 patients), and BCOR (3 patients). Patients with CHIP were older and more frequently had a history of hypertension. During a median follow-up of 4.4 years, a total of 53 patients died, and 23 patients required hospitalization for heart failure. There was a significantly worse long-term clinical outcome for patients with either DNMT3A or TET2 mutations compared with non-CHIP carriers. By multivariable Cox proportional regression analysis, the presence of somatic mutations within TET2 or DNMT3A (HR, 2.1; 95% CI, 1.1-4.0; P = .02, for death combined with heart failure hospitalization) and age (HR, 1.04; 95% CI, 1.01-1.07 per year; P = .005) but not a history of hypertension remained independently associated with adverse outcome. Importantly, there was a significant dose-response association between VAF and clinical outcome.

Conclusions and Relevance  Our data suggest that somatic mutations in hematopoietic cells, specifically in the most commonly mutated CHIP driver genes TET2 and DNMT3A, may be significantly associated with the progression and poor prognosis of CHF. Future studies will have to validate our findings in larger cohorts and address whether targeting specific inflammatory pathways may be valuable for precision medicine in patients with CHF carrying specific mutations encoding for CHIP.

Sign in to take quiz and track your certificates

Buy This Activity
Article Information

Corresponding Author: Andreas M. Zeiher, MD, Department of Medicine III, Cardiology/Angiology/Nephrology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany (zeiher@em.uni-frankfurt.de).

Accepted for Publication: October 8, 2018.

Published Online: December 19, 2018. doi:10.1001/jamacardio.2018.3965

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Dorsheimer L et al. JAMA Cardiology.

Author Contributions: Drs Zeiher and Rieger had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Ms Dorsheimer and Dr Assmus contributed equally as first authors. Drs Dimmeler, Zeiher, and Rieger contributed equally as last authors.

Concept and design: Ortmann, Serve, Dimmeler, Zeiher, Rieger.

Acquisition, analysis, or interpretation of data: Dorsheimer, Assmus, Rasper, Ecke, Abou-El-Ardat, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger, Zeiher, Rieger.

Drafting of the manuscript: Assmus, Zeiher, Rieger.

Critical revision of the manuscript for important intellectual content: Dorsheimer, Rasper, Ortmann, Ecke, Abou-El-Ardat, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger, Dimmeler, Zeiher.

Statistical analysis: Assmus, Ecke, Abou-El-Ardat, Wagner.

Obtained funding: Serve, Dimmeler, Zeiher, Rieger.

Administrative, technical, or material support: Dorsheimer, Rasper, Ortmann, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger.

Supervision: Dorsheimer, Wagner, Serve, Zeiher, Rieger.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Assmus reported personal fees from Novartis, Vifor, Boehringer, and Bayer and grants and personal fees from Abbott outside the submitted work. Dr Serve reported grants from German Cancer Consortium during the conduct of the study. Dr Dimmeler reported grants from BMBF/DZHK during the conduct of the study. Dr. Zeiher reported grants from German Research Foundation and grants from BMBF during the conduct of the study; personal fees from Sanofi, Pfizer, Amgen, and Boehringer Ingelheim; and other fees from T2cure outside the submitted work. Dr Rieger reported grants from Deutsche Forschungsgemeinschaft during the conduct of the study. No other disclosures were reported.

Funding/Support: The study was supported by the German Research Foundation (SFB 834; project B6 to Drs Assmus, Hoffmann, and Zeiher and Z1 to Ms Dorsheimer and Dr Rieger), the Excellence Cluster Cardiopulmonary Systems, project RI2462/1–1 (Dr Rieger), and by the German Center for Cardiovascular Research, Berlin, Germany, partner site Frankfurt Rhine-Main.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Marga Müller-Ardogan, RN, Department of Cardiology, University of Frankfurt, Frankfurt, Germany for excellent technical support and patient care.

References
1.
Genovese  G, Kähler  AK, Handsaker  RE,  et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.  N Engl J Med. 2014;371(26):2477-2487. doi:10.1056/NEJMoa1409405PubMedGoogle ScholarCrossref
2.
Jaiswal  S, Fontanillas  P, Flannick  J,  et al.  Age-related clonal hematopoiesis associated with adverse outcomes.  N Engl J Med. 2014;371(26):2488-2498. doi:10.1056/NEJMoa1408617PubMedGoogle ScholarCrossref
3.
Steensma  DP, Bejar  R, Jaiswal  S,  et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.  Blood. 2015;126(1):9-16. doi:10.1182/blood-2015-03-631747PubMedGoogle ScholarCrossref
4.
Jaiswal  S, Natarajan  P, Silver  AJ,  et al.  Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.  N Engl J Med. 2017;377(2):111-121. doi:10.1056/NEJMoa1701719PubMedGoogle ScholarCrossref
5.
Zhang  Q, Zhao  K, Shen  Q,  et al.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.  Nature. 2015;525(7569):389-393. doi:10.1038/nature15252PubMedGoogle ScholarCrossref
6.
Leoni  C, Montagner  S, Rinaldi  A,  et al.  Dnmt3a restrains mast cell inflammatory responses.  Proc Natl Acad Sci U S A. 2017;114(8):E1490-E1499. doi:10.1073/pnas.1616420114PubMedGoogle ScholarCrossref
7.
Fuster  JJ, MacLauchlan  S, Zuriaga  MA,  et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.  Science. 2017;355(6327):842-847. doi:10.1126/science.aag1381PubMedGoogle ScholarCrossref
8.
Sano  S, Oshima  K, Wang  Y, Katanasaka  Y, Sano  M, Walsh  K.  CRISPR-Mediated gene editing to assess the roles of tet2 and dnmt3a in clonal hematopoiesis and cardiovascular disease.  Circ Res. 2018;123(3):335-341. doi:10.1161/CIRCRESAHA.118.313225PubMedGoogle ScholarCrossref
9.
Sano  S, Oshima  K, Wang  Y,  et al.  Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome.  J Am Coll Cardiol. 2018;71(8):875-886. doi:10.1016/j.jacc.2017.12.037PubMedGoogle ScholarCrossref
10.
Vigen  R, Maddox  TM, Allen  LA.  Aging of the United States population: impact on heart failure.  Curr Heart Fail Rep. 2012;9(4):369-374. doi:10.1007/s11897-012-0114-8PubMedGoogle ScholarCrossref
11.
Westman  PC, Lipinski  MJ, Luger  D,  et al.  Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction.  J Am Coll Cardiol. 2016;67(17):2050-2060. doi:10.1016/j.jacc.2016.01.073PubMedGoogle ScholarCrossref
12.
Assmus  B, Honold  J, Schächinger  V,  et al.  Transcoronary transplantation of progenitor cells after myocardial infarction.  N Engl J Med. 2006;355(12):1222-1232. doi:10.1056/NEJMoa051779PubMedGoogle ScholarCrossref
13.
Assmus  B, Alakmeh  S, De Rosa  S,  et al.  Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.  Eur Heart J. 2016;37(21):1659-1666. doi:10.1093/eurheartj/ehv559PubMedGoogle ScholarCrossref
14.
Assmus  B, Walter  DH, Seeger  FH,  et al.  Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial.  JAMA. 2013;309(15):1622-1631. doi:10.1001/jama.2013.3527PubMedGoogle ScholarCrossref
15.
Assmus  B, Schächinger  V, Teupe  C,  et al.  Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI).  Circulation. 2002;106(24):3009-3017. doi:10.1161/01.CIR.0000043246.74879.CDPubMedGoogle ScholarCrossref
16.
Andrews  S. FastQC: a quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
17.
Smith  T, Heger  A, Sudbery  I.  UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy.  Genome Res. 2017;27(3):491-499. doi:10.1101/gr.209601.116PubMedGoogle ScholarCrossref
18.
Marth  G. Haplotype-based Variant Detection from Short-read Sequencing. arXiv preprint arXiv:12073907 [q-bioGN] 2012.
19.
Cingolani  P, Platts  A, Wang  L,  et al.  A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.  Fly (Austin). 2012;6(2):80-92. doi:10.4161/fly.19695PubMedGoogle ScholarCrossref
20.
Gerszten  RE, Garcia-Zepeda  EA, Lim  YC,  et al.  MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.  Nature. 1999;398(6729):718-723. doi:10.1038/19546PubMedGoogle ScholarCrossref
21.
Ridker  PM, Everett  BM, Thuren  T,  et al; CANTOS Trial Group.  Antiinflammatory therapy with canakinumab for atherosclerotic disease.  N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914PubMedGoogle ScholarCrossref
22.
Guo  S, Jiang  X, Wang  Y,  et al.  The protective role of TET2 in erythroid iron homeostasis against oxidative stress and erythropoiesis.  Cell Signal. 2017;38:106-115. doi:10.1016/j.cellsig.2017.07.002PubMedGoogle ScholarCrossref
23.
Cimmino  L, Dolgalev  I, Wang  Y,  et al.  Restoration of TET2 function blocks aberrant self-renewal and leukemia progression.  Cell. 2017;170(6):1079-1095.e20. doi:10.1016/j.cell.2017.07.032PubMedGoogle ScholarCrossref
24.
Abelson  S, Collord  G, Ng  SWK,  et al.  Prediction of acute myeloid leukaemia risk in healthy individuals.  Nature. 2018;559(7714):400-404. doi:10.1038/s41586-018-0317-6PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements